Targeting HSP90: A Novel Approach to Combat Synovial Sarcomas

Authors

Peyton Worley, Brigham Young University - ProvoFollow
Jared Barrott, Brigham Young University - ProvoFollow
Matt Kirkham, Brigham Young University - Provo
Drake Heithoff, Brigham Young University - Provo

Files

Keywords

HSP90 Inhibitor, synovial sarcoma, cancer

Abstract

Synovial sarcomas are rare muscle cancers that have very few targeted therapies. HSP90 is a protein upregulated in this form of cancer and many others. A screening of this cancer was done in vitro, using FDA-approved drugs, showing that HSP90 could be a promising treatment option. A novel HSP90 inhibitor was applied to human and mouse synovial sarcoma cell lines and was analyzed after receiving a drug treatment for HSP90.

BYU ScholarsArchive Citation

Worley, Peyton; Barrott, Jared; Kirkham, Matt; and Heithoff, Drake, "Targeting HSP90: A Novel Approach to Combat Synovial Sarcomas" (2024). Library/Life Sciences Undergraduate Poster Competition 2024. 17.
https://scholarsarchive.byu.edu/library_studentposters_2024/17

Document Type

Poster

Publication Date

2024-03-21

Language

English

College

Life Sciences

Department

Cell Biology and Physiology

University Standing at Time of Publication

Senior

Copyright Use Information

https://lib.byu.edu/about/copyright/